anmelden
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
Werte in diesem Artikel
SB Investment Advisers (UK) Ltd reported a sale of 2,168,884 shares of Vir Biotechnology (NASDAQ:VIR) in its May 15, 2026, SEC filing, an estimated $17.28 million trade based on quarterly average pricing.According to an SEC filing dated May 15, 2026, SB Investment Advisers (UK) Ltd reduced its stake in Vir Biotechnology by 2,168,884 shares during the first quarter. The estimated value of the shares sold was $17.28 million, calculated using the mean unadjusted closing price for the quarter. The quarter-end value of the position, including market movements, declined by $19.00 million.Vir Biotechnology, Inc. is a commercial-stage biotechnology company specializing in the development of innovative immunology-based therapies for infectious diseases. The company leverages strategic collaborations and advanced research capabilities to address unmet medical needs in global health. Its diversified pipeline and partnerships with leading institutions position it for potential long-term growth in the biotechnology sector.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Vir Biotechnology
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Vir Biotechnology
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: MotleyFool